Department of Pharmacy, DiFAR, University of Genoa, Genoa, Italy.
National Research Council, Institute of Biophysics, Genoa, Italy.
Br J Pharmacol. 2017 Dec;174(24):4785-4796. doi: 10.1111/bph.14061. Epub 2017 Oct 29.
We recently proposed the existence of mGlu -preferring autoreceptors in spinal cord terminals and of mGlu -preferring autoreceptors in cortical terminals. This study aims to verify our previous conclusions and to extend their pharmacological characterization.
We studied the effect of LY566332, an mGlu receptor positive allosteric modulator (PAM), and of LY2389575, a selective mGlu receptor negative allosteric (NAM) modulator, on the mGlu agonist LY379268-mediated inhibition of glutamate exocytosis [measured as KCl-evoked release of preloaded [ H]-D-aspartate]. The mGlu PAM BINA and the mGlu NAM ML337, as well as selective antibodies recognizing the N-terminal of the receptor proteins, were used to confirm the pharmacological characterization of the native receptors.
Cortical synaptosomes possess LY566332-sensitive autoreceptors that are slightly, although significantly, susceptible to LY2389575. In contrast, LY566332-insensitive and LY2389575-sensitive autoreceptors are present in spinal cord terminals. BINA and ML337 mimicked LY566332 and LY2389575, respectively, in controlling LY379268-mediated inhibition of glutamate exocytosis from both cortical and spinal cord synaptosomes. Incubation of cortical synaptosomes with anti-mGlu antibody prevented the LY379268-induced inhibition of glutamate exocytosis, and this response was partially reduced by the anti-mGlu antibody. Incubation of spinal cord synaptosomes with the anti-mGlu antibody abolished LY379268-mediated reduction of glutamate exocytosis from these terminals, while the anti-mGlu antibody was inactive. Western blot analysis and confocal microscopy data were largely consistent with these functional observations.
We confirmed that mGlu -preferring autoreceptors exist in spinal cord terminals. Differently, cortical glutamatergic terminals possess mGlu /mGlu heterodimers, whose inhibitory effect is largely mediated by mGlu receptors.
我们最近提出了脊髓末端存在 mGlu- 优先自身受体,以及皮质末端存在 mGlu- 优先自身受体。本研究旨在验证我们之前的结论,并扩展其药理学特征。
我们研究了 mGlu 受体正变构调节剂 (PAM) LY566332 和选择性 mGlu 受体负变构调节剂 (NAM) LY2389575 对 mGlu 激动剂 LY379268 介导的谷氨酸外排抑制作用的影响[以 KCl 诱发的预先加载的[H]-D-天冬氨酸释放来衡量]。使用 mGlu PAM BINA 和 mGlu NAM ML337 以及识别受体蛋白 N 端的选择性抗体,来确认对天然受体的药理学特征的确认。
皮质突触体具有 LY566332 敏感的自身受体,尽管敏感性略有增加,但对 LY2389575 敏感。相反,脊髓末端存在 LY566332 不敏感和 LY2389575 敏感的自身受体。BINA 和 ML337 分别模拟了 LY566332 和 LY2389575,控制 LY379268 介导的从皮质和脊髓突触体的谷氨酸外排抑制作用。用抗 mGlu 抗体孵育皮质突触体可防止 LY379268 诱导的谷氨酸外排抑制,而该反应部分被抗 mGlu 抗体所减少。用抗 mGlu 抗体孵育脊髓突触体可消除这些末端的 LY379268 介导的谷氨酸外排减少,而抗 mGlu 抗体则没有作用。Western blot 分析和共聚焦显微镜数据与这些功能观察结果基本一致。
我们证实了 mGlu- 优先自身受体存在于脊髓末端。不同的是,皮质谷氨酸能末端存在 mGlu/mGlu 异源二聚体,其抑制作用主要由 mGlu 受体介导。